Cannabis Bioscience Reports 86% Revenue Decline and Increased Net Loss for Quarter Ending August 31, 2025

Cannabis Bioscience International Holdings, Inc. reported a significant decline in financial performance for the quarter ending August 31, 2025, with revenues dropping to $24,200 from $178,887 in the same period last year. This decrease of approximately 86% was primarily attributed to a reduction in clinical trial contracts, which fell from $178,386 to $24,139. The company also experienced a decline in online sales of educational materials, which decreased from $501 to $61. Despite a slight reduction in cost of revenues, gross profit fell sharply from $170,525 to $16,057, reflecting the overall downturn in revenue.

Operating expenses for the quarter were reported at $90,841, down from $268,129 in the previous year, largely due to a significant reduction in share-based compensation, which was eliminated in the current quarter compared to $100,000 in the prior year. Other reductions included general and administrative expenses and professional fees. As a result, the operating loss improved to $74,784 from $97,604 year-over-year. However, the company still reported a net loss of $82,645, compared to a loss of $76,305 in the prior year, indicating ongoing financial challenges.

The company’s balance sheet as of August 31, 2025, showed total assets of $18,942, a decrease from $31,880 as of May 31, 2025. Current liabilities increased to $1,015,670 from $945,963, with a notable rise in related-party payables, which reached $717,275. The accumulated deficit also widened to $5,965,546 from $5,882,901, highlighting the ongoing financial strain. The company had only $223 in cash and cash equivalents at the end of the reporting period, down from $12,952, raising concerns about liquidity.

In terms of strategic developments, Cannabis Bioscience continues to focus on its core operations, which include clinical trials, cannabis-related education, and CBD product sales. The company has not reported any significant acquisitions or new product launches during this quarter. However, it has indicated a need for substantial additional capital to fund operations and repay debts, emphasizing the importance of executing its operating plan to increase sales and potentially raise financing. The company’s ability to continue as a going concern remains uncertain, as it has not generated sufficient income to cover operating expenses since its inception.

Looking ahead, the company acknowledges the challenges it faces in securing financing and expanding operations. Management has expressed that the successful execution of its operating plan is critical for future viability. The company’s financial statements reflect a need for strategic adjustments to improve its market position and financial health, as it navigates a competitive landscape in the cannabis industry.